Delcath Systems Reports Second Quarter 2026 Results and Business Highlights

Increases 2026 Revenue Guidance to a Range of $104M to $108M

Conference Call Today at 8:30 a.m. Eastern Time

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2026.

Second Quarter 2026 Financial Results